Serina Therapeutics is shedding a subsidiary to start the new year off debt-free. | Serina Therapeutics is shedding a ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Take a look back at the biggest stories of the week with Fierce Biotech’s conference's kickoff coverage here | Welcome to day ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...